Dermira’s Co-founder and Chief Medical Officer, Eugene A. Bauer, M.D., Receives Presidential Citation from the American Academy of Dermatology
14 mars 2016 07h30 HE
|
Dermira, Inc.
MENLO PARK, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
03 mars 2016 07h30 HE
|
Dermira, Inc.
MENLO PARK, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira to Report Fourth Quarter and Full Year 2015 Financial Results
01 mars 2016 16h05 HE
|
Dermira, Inc.
MENLO PARK, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira to Present at Cowen and Company 36th Annual Health Care Conference
01 mars 2016 07h30 HE
|
Dermira, Inc.
MENLO PARK, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary Hyperhidrosis
29 févr. 2016 07h30 HE
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Completes Patient Enrollment for Third CIMZIA® (certolizumab pegol) Phase 3 Clinical Trial in Psoriasis Program and Updates Guidance for Release of Topline Data
08 janv. 2016 01h00 HE
|
Dermira, Inc.
Enrollment for All Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Plaque Psoriasis Completed Dermira Plans to Announce Topline Data for Phase 3 Trials by End of First Quarter...
Dermira Provides DRM01 and DRM04 Development Program Updates
07 janv. 2016 16h05 HE
|
Dermira, Inc.
Enrollment Completed in DRM01 Phase 2b Acne Trial; Topline Data Expected in 2Q16 Topline Data for DRM04 Phase 3 Hyperhidrosis Program Expected Mid-2016 MENLO PARK, Calif., Jan. 07, 2016 (GLOBE...
Dermira Added to NASDAQ Biotechnology Index
15 déc. 2015 07h00 HE
|
Dermira, Inc.
MENLO PARK, Calif., Dec. 15, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to...
Dermira Completes Patient Enrollment for Second CIMZIA(R) (certolizumab pegol) Phase 3 Clinical Trial in Psoriasis Program
19 nov. 2015 07h00 HE
|
Dermira, Inc.
MENLO PARK, Calif., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists...
Dermira Completes Patient Enrollment for First CIMZIA(R) (Certolizumab Pegol) Phase 3 Clinical Trial in Psoriasis Program
12 oct. 2015 16h21 HE
|
Dermira, Inc.
MENLO PARK, Calif., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists...